Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Symposium on Signalling Pathways in Cancer 2018

23 - 24 Mar 2018

Barcelona, Spain

Signalling Pathways 2018 - square

ESMO Symposium on Signalling Pathways in Cancer, in partnership with the European Association for Cancer Research (EACR), will focus on Cyclin-dependent kinases (CDKs). Presentations and webcasts from the ESMO Symposium on Signalling Pathways in Cancer 2018 are available here to ESMO members.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings

Video report from Violetta Serra on Understanding the Mecanism of Resistance to CDK4/6 Inhibitors

Most of oestrogen receptor positive metastatic breast cancer patients are receiving CDK4/6 inhibitors, now approved for first-line treatment. Violetta Serra explains that the challenge is now to identify resistance to these drugs in order to establish potential second line treatments.

Filter by:

There are 26 resources available

Welcome to the Symposium

Presenter: Josep Tabernero

Session: Welcome and introduction




CDK 4-6 inhibition

Presenter: Monica Arnedos

Session: The concept of CDK inhibition according to the targeted CDK subtype




This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings